Home Authors Posts by

Giuliana Miglierini

112 POSTS

The containment of highly potent active pharmaceutical ingredients

Gene editing. The first recommendations on allowed use

Neurodegenerative diseases. The role of dopaminergic neurons

Regulatory challenges of CAR-T cell therapies

The new ICH E11 (R1) on pediatric studies

Biosimilars to provide better access at sustainable costs

The new FDA guidelines on Quality Metrics

Manufacturing classification system

Germany: The Rx-mail order German affair

Many new clinical guidelines from EMA

1...8910...12Page 9 of 12

Newsstand

  • Supplement to n.5 - October 2025 NCF International n.2 - 2025
  • NCF International n.1 - 2025
  • Supplemento to n.9 - October 2024 NCF International n.3 - 2024
Newsstand
© © 2026 Tecniche Nuove Spa - All rights reserved. Registered office: Via Eritrea 21 - 20157 Milan. Share capital: 5,000,000 Euro fully paid up. Tax code, VAT number and registration with the Milan Register of Companies: 00753480151